Wednesday , November 22 2017
Home / Multiple Sclerosis

Multiple Sclerosis

Sanofi Signs License Deal with Principia Biopharma for Multiple Sclerosis Drug Candidate

Paris, France and South San Francisco, Calif – November 9, 2017 – Sanofi will develop Principia Biopharma Inc.’s experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous system (CNS) diseases. Under the license agreement signed this week, Sanofi will develop Principia’s Bruton’s tyrosine kinase (BTK) …

Read More »

Studies Find Approximately Half of Patients Do Not Always Engage with Healthcare Professionals During Multiple Sclerosis Relapse

STAINES-UPON-THAMES, United Kingdom, Oct. 27, 2017 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced results from two company-sponsored surveys – the Multiple Sclerosis in America 2017 Survey (Poster P805) and a national patient survey conducted by Harris Poll (Poster P1267) – that suggest patient-reported …

Read More »

Data Suggests Slowing of Cortical Gray Matter Atrophy with Aubagio Delays Conversion to Clinically Definitive Multiple Sclerosis

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today new investigational data that suggest slowing of cortical gray matter volume loss (atrophy) with Aubagio® (teriflunomide) is associated with delayed conversion to clinically definite multiple sclerosis (CDMS). The data, from the Phase III TOPIC study in patients with …

Read More »

Abzena and UGA Biopharma Team Up to Develop a Cell Line Expressing a Biosimilar Therapeutic for Multiple Sclerosis

CAMBRIDGE, England & HENNIGSDORF, Germany–(BUSINESS WIRE)–Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing integrated solutions and technologies enabling the development and manufacture of biopharmaceutical products, and UGA Biopharma GmbH, a cell line development specialist, announce the completion of the development of a biosimilar cell line …

Read More »

FDA Approves Mylan’s Generic Version of Teva’s Multiple Sclerosis Drug Copaxone

HERTFORDSHIRE, England, and PITTSBURGH, Oct. 3, 2017 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) today announced that the U.S. Food and Drug Administration (FDA) has approved Mylan’s Abbreviated New Drug Applications (ANDAs) for Glatiramer Acetate Injection 40 mg/mL for 3-times-a-week injection, an AP-rated, substitutable generic version of Teva’s Copaxone® 40 …

Read More »

Unique Gene Therapy Prevents, Reverses Multiple Sclerosis in Animal Model

Multiple sclerosis can be inhibited or reversed using a novel gene therapy technique that stops the disease’s immune response in mouse models, University of Florida Health researchers have found. By combining a brain-protein gene and an existing medication, the researchers were able to prevent the mouse version of multiple sclerosis. …

Read More »

New Imaging Technique Able to Watch Molecular Dynamics of Neurodegenerative Diseases

WASHINGTON — Researchers have developed a fast and practical molecular-scale imaging technique that could let scientists view never-before-seen dynamics of biological processes involved in neurodegenerative diseases such as Alzheimer’s disease and multiple sclerosis. The new technique reveals a sample’s chemical makeup as well as the orientation of molecules making up …

Read More »

FDA Expands Approval of Ipsen’s Dysport for the Treatment of Lower Limb Spasticity in Adults

BASKING RIDGE, N.J.–(BUSINESS WIRE)–Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved use of Dysport®(abobotulinumtoxinA) for injection for the treatment of spasticity in adults, based on its supplemental Biologics License Application (sBLA) …

Read More »

Celgene Ozanimod Demonstrates Positive Results in Second Late-Stage Trial in Relapsing Multiple Sclerosis

SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) today announced that its phase III RADIANCE trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly …

Read More »

Teva and Active Biotech’s Laquinimod Fails to Meet Primary Endpoint in Phase 3 Multiple Sclerosis Trial

JERUSALEM & LUND, Sweden–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from the CONCERTO trial in patients with relapsing-remitting multiple sclerosis (RRMS). The primary endpoint in CONCERTO — the evaluation of laquinimod (0.6 mg/daily capsules) versus placebo to evaluate …

Read More »